BOPA 2017 | The introduction of biosimilar rituximab: a case study from the pharmacist’s perspective
VJHemOnc is committed to improving our service to you
Thanks for your feedback, this will help us improve our content for you!
During the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium for cancer care pharmacy in Glasgow, UK, Simon Cheesman, BPharm, MRPharmS from the University College London Hospital (UCLH) , London, UK, discusses how they have introduced biosimilar rituximab into clinical practice at UCLH. He shares the key considerations when making the switch and emphasizes the pharmacists’ role in driving things forward, as well as summarising the data they have obtained so far in hematological malignancies.
This content has been supported by Napp Pharmaceuticals through an unrestricted educational grant to Magdalen Medical Publishing. The company has had no influence on the production of the content.
Get great new content delivered to your inboxSign up